Abstract
Ultraviolet radiation (UV) is causally linked to cutaneous melanoma, yet the underlying epigenetic mechanisms, known as molecular sensors of exposure, have never been characterized in clinical biospecimen. Here, we integrate clinical and epigenome (DNA methylome), genome and transcriptome profiling of 112 cutaneous melanoma from two multi-ethnic cohorts. We identify UV-related alterations in regulatory regions and immunological pathways, with multi-OMICs cancer driver potential affecting patient survival. TAPBP, the top gene, is critically involved in immune function and encompasses several UV-altered methylation sites that were validated by targeted sequencing, providing cost-effective opportunities for clinical application. The DNA methylome also reveals non UV-related aberrations underlying pathological differences between the cutaneous and 17 acral melanomas. Unsupervised epigenomic mapping demonstrated that non UV-mutant cutaneous melanoma more closely resembles acral rather than UV-exposed cutaneous melanoma, with the latter showing better patient prognosis than the other two forms. These gene-environment interactions reveal translationally impactful mechanisms in melanomagenesis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We thank all melanoma patients who contributed to the study. This work was supported by Public Ministry of Labor, Campinas (Research, Prevention, and Education of Occupational Cancer), Barretos Cancer Hospital and International Agency for Research on Cancer. A.L.S.A.V. was supported by FAPESP (grant no 2016/15941-3 and 2017/09612-0). We thank the BCH biobank for DNA isolation and sample processing and storage. The initial development of the multi-OMICs driver score was partially supported by the grant from the Institut National du Cancer (INCa, France), La direction generale de loffre de soins (DGOS), and INSERM (SIRIC LYriCAN, INCa-DGOS-Inserm_12563) to Z.H.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the Brazilian national and institutional ethical policies, and it was previously approved by the Barretos Cancer Hospital Ethics Committee (716/2013).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The 450K data generated in this study have been deposited in the GEO database under accession code GSE202750 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE202750]. The WGS data are available in the ICGC database [https://dcc.icgc.org/projects/SKCA-BR]. The 450K, RNAseq and WES data on melanoma samples from TCGA were downloaded from the GDC Legacy Portal [https://portal.gdc.cancer.gov/legacy-archive/search/f] and cBioPortal [https://www.cbioportal.org/datasets].
https://drive.google.com/drive/folders/1LG4HbM6aeRL4TME0aykcUshDKGSHIbPT?usp=sharing
